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he Prognostic Value of
onocyte Chemoattractant
rotein-1/CCL2 in Acute
oronary Syndromes*
ikolaos G. Frangogiannis, MD, FACC
ouston, Texas
he chemokines are a family of small heparin-binding
roteins with a strikingly similar tertiary structure. There
re approximately 50 human chemokines, and they can be
lassified into CC, CXC, C, or CX3C subfamilies based on
he number of amino acids between the first 2 of the 4
onserved cysteine residues that characterize chemokine
tructure. Monocyte chemoattractant protein (MCP)-1/
CL2, the most thoroughly characterized CC chemo-
ine, was identified as a monocyte-specific chemoattrac-
ant that was later shown to attract T lymphocytes and
atural killer cells, but not neutrophils. Enhanced expres-
ion of MCP-1 was shown in a variety of pathological
onditions, associated with inflammation and mononuclear
ell infiltration.
See page 2117
Inflammation plays a crucial role in the initiation and
rogression of atherosclerotic disease and may be critically
nvolved in the pathogenesis of plaque rupture and throm-
osis. In the early stages of atherosclerosis blood monocytes
iapedese into the subendothelium, where they ingest lipid
o become the foam cells of the fatty streak. Extensive
xperimental evidence suggests that MCP-1 is highly ex-
ressed in atherosclerotic plaques (1) and mediates macro-
hage recruitment in the atheromatous lesion. Oxidized
ipids mediate foam cell formation and have long been
mplicated as important mediators of atherosclerosis. Min-
mally oxidized low-density lipoproteins (LDLs) but not
ative LDLs induce MCP-1 production in vascular endo-
helial and smooth muscle cells (2). Thus, MCP-1 may be
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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R01 HL-76246) and the American Heart Association.he molecular link between oxidized lipoproteins and foam
ell recruitment into the vessel wall. Deletion of the MCP-1
ene in LDL receptor-deficient mice (3) and in animals
verexpressing human apolipoprotein B (4) protected from
he development of diet-induced atherosclerosis, dramati-
ally reducing macrophage recruitment in the aortic wall,
ithout altering lipoprotein metabolism.
The potential role of MCP-1 in the progression of
therosclerotic disease and plaque rupture is less established.
onocyte chemoattractant protein-1 induces smooth mus-
le cell proliferation and may exert angiogenic effects pro-
oting neovessel formation in the plaque; these actions may
ead to rapid progression of the lesion. Additionally,
CP-1 may play a role in disruption of the atherosclerotic
laque by inducing matrix metalloproteinase expression and
elease. Also, MCP-1 may have procoagulant properties,
nducing tissue factor synthesis and activity in smooth
uscle cells (5). Although direct proof of the in vivo
ignificance of these mechanisms is lacking, an inhibitory
ntibody to MCP-1 and -5 administered to apolipoprotein
/ mice induced a stable plaque phenotype with in-
reased collagen content (6).
In addition to its established role in the pathogenesis of
therosclerotic disease and its potential significance in
isease progression and plaque rupture, MCP-1 is also
ritically involved in the healing response after an acute
oronary event (7). Myocardial infarction triggers a local
nflammatory reaction that results in formation of a scar and
s closely intertwined with remodeling of the infarcted
entricle. Monocyte chemoattractant protein-1 expression is
arkedly but transiently induced in infarcted hearts and
ritically regulates the healing response. Monocyte che-
oattractant protein-1 null mice show reduced macrophage
nfiltration, delayed phagocytosis of dead cardiomyocytes,
nd suppressed cytokine synthesis followed by decreased
yofibroblast accumulation in the infarcted myocardium. In
he absence of MCP-1, suppression of the inflammatory
esponse and reduced fibroblast infiltration result in atten-
ated dilative remodeling of the infarcted ventricle (8).
uring the inflammatory stage of infarct healing, MCP-1
ediates macrophage recruitment and timely clearance of
ead cells from the infarct; however, prolonged induction of
he chemokine in the infarcted heart may result in extension
f granulation tissue formation and adverse remodeling of
he ventricle (9). Thus, timely resolution of the inflamma-
ory response after myocardial infarction is critical for
ptimal healing.
The potential involvement of MCP-1 in the pathogenesis
f myocardial infarction and cardiac remodeling does not
ecessarily imply that plasma levels of MCP-1 can serve for
isk prediction in patients with acute coronary syndromes
ACS) (10). Plasma MCP-1 levels may not reflect the
ctivation of the MCP-1 axis in the vascular wall or the
nfarcted heart because of immobilization of the chemokine
n the luminal surface of endothelial cells. Binding to
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Editorial Comment November 27, 2007:2125–7lycosaminoglycan chains of cell surface proteoglycans is
ssential for MCP-1 actions in vivo, ensuring high local
oncentrations of MCP-1 and providing directional signals
or monocyte migration. In addition, pharmacological in-
erventions may influence plasma chemokine levels in pa-
ients with ACS. Despite these theoretical concerns, clinical
nvestigations have suggested that in patients with ACS,
igh baseline plasma MCP-1 levels are associated with an
ncreased risk of death and recurrent ischemic events inde-
endent of standard risk predictors (11). These studies
uggested that MCP-1 may be an attractive surrogate
iomarker in patients with ACS.
In this issue of the Journal, de Lemos et al. (12) examined
hether serial measurement of plasma MCP-1 levels in a
arge population of patients with an ACS adds prognostic
alue to standard risk assessment tools and established
iomarkers. After adjustment for standard risk predictors
nd levels of C-reactive protein and B-type natriuretic
eptide, high baseline MCP-1 levels remained indepen-
ently associated with long-term mortality and major ad-
erse cardiac outcomes. In addition, MCP-1 levels mea-
ured 4 months after the coronary event also provided
ndependent prognostic information. The study extends
revious investigations suggesting that MCP-1 may be
aluable for risk stratification of patients in both the
arly and late stage after an acute coronary event. In
Figure 1 Why Do Patients With Elevated Plasma MCP-1 Levels
(A) High plasma monocyte chemoattractant protein (MCP)-1 levels may reflect incr
erosclerotic disease. Monocyte chemoattractant protein-1 is immobilized on the lu
mononuclear cell (M) recruitment into the subendothelial space. Monocytes differe
chemoattractant protein-1 is involved in FC formation, one of the earliest manifest
contribute to progression of atherosclerotic disease through FC activation, stimula
tion (V, neovessel). Also, MCP-1 may induce matrix metalloproteinase (MMP) synth
sue factor (TF) expression exerting procoagulant effects. (C) Prolonged increas
patients showing an enhanced inflammatory response in the healing myocardiu
phase of healing mediates macrophage recruitment resulting in clearance of th
pathogenesis of adverse remodeling. Timely repression of MCP-1 synthesis is
of the infarcted ventricle.ddition, the findings raise an intriguing question regard-
ng the potential role of MCP-1 in patients with coronary
isease. Why do patients with persistently elevated
CP-1 plasma levels have adverse outcomes after an
CS event?
Several distinct mechanisms may be responsible for the
dverse prognosis of patients with elevated MCP-1 levels
Fig. 1). First, baseline elevation of plasma MCP-1 may
eflect enhanced expression of the chemokine in athero-
clerotic lesions, resulting in increased macrophage re-
ruitment and more extensive atherosclerotic disease. Sec-
nd, enhanced systemic activation of the MCP-1 axis may
xert prothrombotic effects resulting in recurrent coronary
vents. Third, enhanced and prolonged elevation of plasma
CP-1 may identify patients who mount a more intense
ardiac inflammatory reaction after a coronary event, or show
mpaired resolution of the post-infarction inflammatory
esponse. Sustained inflammation after the acute event may
esult in adverse cardiac remodeling. It should be noted that
he baseline levels of MCP-1 after an acute coronary event
o not seem to reflect the extent of injury. Because in the A
o Z (Aggrastat to Zocor) study troponin levels were not
easured in a core laboratory, quantitative evaluation of the
elation between MCP-1 levels and the extent of cardiomy-
cyte injury was not possible. However, in the OPUS-TIMI
Orbofiban in Patients with Unstable coronary Syndromes-
Adverse Prognosis After an ACS Event?
synthesis of the chemokine by vascular cells leading to more extensive ath-
surface of the endothelium through binding with proteoglycans and mediates
into macrophages (Ma) and ingest lipids to form foam cells (FCs). Monocyte
of atherosclerosis. (B) Enhanced expression of MCP-1 in the vascular wall may
smooth muscle cell (SMC) proliferation, and induction of plaque neovasculariza-
promoting matrix degradation and plaque disruption, and may up-regulate tis-
lasma MCP-1 levels after an acute coronary syndrome event may identify
e induction of MCP-1 in the infarcted myocardium during the inflammatory
rct from dead cells and matrix debris, but also seems to play a role in the
for optimal healing; sustained inflammation results in adverse remodelingHave
eased
minal
ntiate
ations
tion of
esis,
e of p
m. Th
e infa
crucial
T
n
t
b
l
r
m
t
l
(
a
n
i
g
e
M
e
b
e
b
s
s
l
M
i
b
f
p
t
d
(
t
w
c
i
i
a
r
t
i
m
f
l
i
R
g
B
E
R
1
1
1
1
1
2127JACC Vol. 50, No. 22, 2007 Frangogiannis
November 27, 2007:2125–7 Editorial Commenthrombolysis In Myocardial Infarction) 16 study, the prog-
ostic association of MCP-1 was independent of cardiac
roponin levels (11).
Although age, cigarette smoking, triglyceride levels, and
ody mass index are clinical correlates of MCP-1 levels in
arge populations, genetic variations play a more important
ole in MCP-1 plasma level variability (13). In the Fra-
ingham Heart Study offspring cohort, individuals carrying
he MCP-1-2578G allele had higher circulating MCP-1
evels and showed an increased risk of myocardial infarction
13). Whether CCL2/MCP-1 polymorphisms are associ-
ted with enhanced serum MCP-1 levels and worse prog-
osis after an ACS event remains to be investigated.
The findings of the study may also have therapeutic
mplications. It has been shown that 3-hydroxy-3-methyl-
lutaryl coenzyme A reductase inhibition decreases MCP-1
xpression in atherosclerotic vessels (14) and reduces plasma
CP-1 levels. It has been suggested that the beneficial
ffects of statins in patients with myocardial infarction may
e mediated through decreased MCP-1 expression. Thus,
levated MCP-1 levels could identify patients more likely to
enefit from aggressive statin treatment. The current study
uggested that the effects of early intensive treatment with
imvastatin are independent of baseline MCP-1 plasma
evels. The modest effects of aggressive statin treatment on
CP-1 levels do not exclude a significant role of MCP-1
nhibition in mediating the beneficial actions of the statins,
ut may suggest that therapeutic interventions aiming at
urther reducing MCP-1 levels in patients with ACS may
rovide additional benefit. Experimental studies have shown
hat disruption of the MCP-1 signaling pathway attenuates
ilative remodeling after reperfused myocardial infarction
8), suggesting that MCP-1 may be a novel pharmacological
arget in patients with acute coronary events. However, a
ord of caution should be raised regarding the potential
onsequences of overly aggressive suppression of MCP-1
n the infarcted myocardium: absence of MCP-1 results
n attenuated post-infarction left ventricular remodeling
t the expense of impaired phagocytosis and delayed
eplacement of injured cardiomyocytes with granulation
issue. Delayed phagocytosis of injured cardiomyocytes may
ncrease the arrhythmogenic potential or predispose to
echanical complications in patients with myocardial in-arction. The effects of MCP-1 inhibition in large mamma-ian models of infarction should be carefully studied before
dentifying MCP-1 as a therapeutic target.
eprint requests and correspondence: Dr. Nikolaos G. Frango-
iannis, Section of Cardiovascular Sciences, One Baylor Plaza
CM620, Baylor College of Medicine, Houston, Texas 77030.
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